Imugene Ltd has released a press release.
Oncolytic Virotherapy CF33 Patent Granted in China
Filed with ASX ·
6ix hasn’t read this filing yet.
Story so far
Earlier from Imugene
- Imugene to present at 2024 Cholangiocarcinoma Conference
- Phase 1 onCARlytics Trial Advances to Combination Arm
- Phase 1 onCARlytics Trial Doses First Intravenous Patient
- VAXINIA Phase 1 trial doses patients in higher dose cohorts
- Phase 1 CF33-hNIS Study Update - Positive Early Signals
Later from Imugene
- VAXINIA and HER-Vaxx featured at the AACR Annual Meeting
- Bile Tract Cancer Study Opens after MAST High Dose Clearance
- Imugene and Kincell Bio Announce Strategic Partnership
- Imugene partners with Kincell Bio; selling cell therapy manufacturing facility for $6 million
- Imugene onCARlytics Doses First Patient in IV Combination
Follow Imugene into a list and get an email when it puts out news.
Follow Imugene